Company News: Johnson & Johnson, PriCara, Novartis and Merck KGaA

Share this article:
Johnson & Johnson's PriCara launched PrescribeResponsibly.com, a website for healthcare professionals on appropriate and responsible prescribing of opioid analgesics including case studies, sections about the role of genetics in pain and response to opioid drugs and info about the importance of considering these factors in prescribing. PriCara makes Duragesic, Ultram ER and Nucynta.
 
Three January New England Journal of Medicine studies showed that oral medications for multiple sclerosis from Novartis and Merck KGaA reduce relapse and worsening of the neurological disease. Patients who took the drugs had higher rates of infections, though. Novartis has applied for US approval of FTY720, while Merck KGaA's Merck Serono unit must resubmit its application for cladrabine after receiving an FDA refuse-to-file letter.
Share this article:

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.